AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy

QJM: An International Journal of Medicine

Volumn 99, Issue 12, 2006, Pages 811-826

  Palmieri, C ^a   Treibel, T ^a   Large, O ^a   Bower, M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIDANOSINE; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; INDINAVIR; LAMIVUDINE; METHOTREXATE; PENTAMIDINE; PREDNISOLONE; PROTEINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEBRILE NEUTROPENIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGAMMAGLOBULINEMIA; KAPOSI SARCOMA; LOW DRUG DOSE; MENINX DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOBACTERIOSIS; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RETINITIS; REVIEW; RISK REDUCTION; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; VIRUS LOAD;

EID: 33845873349     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcl115     Document Type: Review

References (91)

1. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305:1425-31.
2. Harris C, Small CB, Klein RS, Friedland GH, Moll B, Emeson EE, Spigland I, Steigbigel NH. Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309:1181-4.
3. Stebbing J, Bower M. What can oncologists learn from HIV? Lancet Oncol 2003; 4:438-45.
4. Ziegler JL, Templeton AC, Vogel CL. Kaposi's sarcoma: A comparison of classical, endemic, and epidemic forms. Semin Oncol 1984; 11:47-52.
5. Boring CC, Brynes RK, Chan WC, Causey N, Gregory HR, Nadel MR, Greenberg RS. Increase in high-grade lymphomas in young men. Lancet 1985; 1:857-9.
6. Levine AM, Gill PS, Meyer PR, Burkes RL, Ross R, Dworsky RD, Krailo M, Parker JW, Lukes RJ, Rasheed S. Retrovirus and malignant lymphoma in homosexual men. JAMA 1985; 254:1921-5.
7. Stebbing J, Marvin V, Bower M. The evidence-based treatment of AIDS-related non-Hodgkin's lymphoma. Cancer Treat Rev 2004; 30:249-53.
8. Thirlwell C, Sarker D, Stebbing J, Bower M. Acquired immunodeficiency syndrome-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma 2003; 4:86-92.
9. Phelps RM, Smith DK, Heilig CM, Gardner LI, Carpenter CC, Klein RS, Jamieson DJ, Vlahov D, Schuman P, Holmberg SD. Cancer incidence in women with or at risk for HIV. Int J Cancer 2001; 94:753-7.
10. Bower M, Powles T, Nelson M, Shah P, Cox S, Mandelia S, Gazzard B. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 17:371-5.
11. Powles T, Bower M, Daugaard G, Shamash J, de Ruiter A, Johnson M, Fisher M, Anderson J, Mandalia S, Stebbing J, Nelson M, Gazzard B, Oliver T. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol 2003; 21:1922-7.
12. Thomas JO. Acquired immunodeficiency syndrome-associated cancers in Sub-Saharan Africa. Semin Oncol 2001; 28:198-206.
13. N'Galy B, Bertozzi S, Ryder RW. Obstacles to the optimal management of HIV infection/AIDS in Africa. J Acquir Immune Defic Syndr 1990; 3:430-7.
14. Otieno MW, Banura C, Katongole-Mbidde E, Johnson JL, Ghannoum M, Dowlati A,, Renne R, Arts E, Whalen C, Lederman MM, Remick SC. Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa. J Natl Cancer Inst 2002; 94:718-32.
15. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
16. Stebbing J, Gazzard B. Stemming the epidemic: Prevention and therapy go hand-in-hand. J HIV Ther 2003; 8:51-5.
17. Jacobson L. Impact of highly effective anti-retroviral therapy on the incidence of malignancies among HIV infected individuals. J AIDS Hum Retrovirol 1998; 9:A39.
18. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000; 96:2730-4.
19. Beral V, Newton R, Reeves G, collaborators. obotsa. International collaboration on HIV and cancer. J Acquir Immune Defic Syndr 2000; 23:A8.
20. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991; 337:805-9.
21. Biggar RJ, Rosenberg PS, Cote T. Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. Int J Cancer 1996; 68:754-8.
22. Auperin I, Mikolt J, Oksenhendler E, Thiebaut JB, Brunet M, Dupont B, Morinet F. Primary central nervous system malignant non-Hodgkin's lymphomas from HIV-infected and non-infected patients: Expression of cellular surface proteins and Epstein-Barr viral markers. Neuropathol Appl Neurobiol 1994; 20:243-52.
23. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and Non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study. Br Med J 1999; 319:23-4.
24. Inungu J, Melendez MF, Montgomery JP. AIDS-related primary brain lymphoma in Michigan, January 1990 to December 2000. AIDS Patient Care STDS 2002; 16:107-12.
25. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Gazzard B. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17:17-22.
26. Autran B, Carcelain G, Debre P. Immune reconstitution after highly active anti-retroviral treatment of HIV infection. Adv Exp Med Biol 2001; 495:205-12.
27. Lederman M. Immune restoration and CD4+ T-cell function with antiretroviral therapies. AIDS 2001; 15(Suppl. 2):S11-15.
28. International Collaboration on HIV and Cancer: Highly Active Antiretroviral Therapy and Incidence of Cancer in Human Immunodeficiency Virus-Infected Adults. J Natl Cancer Inst 2000; 92:1823-30.
29. Rabkin CS. AIDS and cancer in the era of highly active antiretroviral therapy (HAART). Eur J Cancer 2001; 37:1316-19.
30. Stebbing J, Gazzard B, Mandalia S, Teague A, Waterston A, Marvin V, Nelson M, Bower M. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:2177-83.
31. Wilde JT, Lee CA, Darby SC, Kan SW, Giangrande P, Phillips AN, Winter M, Spooner R, Ludlam CA. The incidence of lymphoma in the UK haemophilia population between 1978 and 1999. AIDS 2002; 16:1803-7.
32. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O, Lundgren JD. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291-6.
33. Fong IW, Ho J, Toy C, Lo B, Fong MW. Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: Case-control and historical cohort studies. Clin Infect Dis 2000; 30:757-61.
34. Bossolasco S, Cinque P, Ponzoni M, Vigano MG, Lazzarin A, Linde A, Falk KI. Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. J Neurovirol 2002; 8:432-8.
35. Van Baarle D, Wolthers KC, Hovenkamp E, Niesters HG, Osterhaus AD, Miedema F, Van Oers MH. Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis 2002; 186:405-9.
36. Sarker D, Thirlwell C, Nelson M, Gazzard B, Bower M. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS 2003; 17:861-5.
37. Massarweh S, Udden MM, Shahab I, Kroll M, Sears DA, Lynch GR, Teh BS, Lu HH. HIV-related Hodgkin's disease with central nervous system involvement and association with Epstein-Barr virus. Am J Hematol 2003; 72:216-19.
38. Desai J, Mitnick R, Henry D, Llena J, Sparano J. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphoma. Cancer 1999; 86:1840-7.
39. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339-44.
40. Kaplan LD, Straus DJ, Testa MA, von Roenn J, Dezube BJ, Cooley TP, Herndier B, Northfelt DW, Huang J, Tulpule A, Levine AM. Low dose compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997; 336:1641-8.
41. Bower M Stern S, Fife K, Nelson M, Gazzard BG. Weekly alternating combination chemotherapy for good prognosis AIDS-related lymphoma. Eur J Cancer 2000; 36:363-7.
42. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, Straus D. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19:2171-8.
43. Gill PS, Levine AM, Krailo M, Rarick MU, Loureiro C, Deyton L, Meyer P, Rasheed S. AIDS-related malignant lymphoma: Results of prospective treatment trials. J Clin Oncol 1987; 5:1322-8.
44. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, Flores A, Milla F, Feliu E. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001; 112:909-15.
45. Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, Vultaggio G, Tirelli U. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91:155-63.
46. Levine AM, Tulpule A, Espina B, Sherrod A, Boswell WD, Lieberman RD, Nathwani BN, Welles L. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 2004; 22:2662-70.
47. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadbum A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma: AIDS-malignancies consortium trial 010. Blood 2005; 24:1538-43.
48. Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio BC, Palmieri F, De Luca A, Larocca LM, Ruco L, Ippolito G, Cauda R. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15:1483-91.
49. Matsushima Y, Kanzawa F, Hoshi A, Shimizu E, Nomori H, Sasaki Y, Saijo N. Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 1985; 14:104-7.
50. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310:1353-6.
51. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PF. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7:1333-40.
52. Sparano JA, Lee S, Henry DH, Ambinder RF, von Roenn J, Tirelli U. Infusional cyclophosphamide, doxorubicin and etoposide in HIV associated non-Hodgkin's lymphoma: A review of the Einstein, Aviano and ECOG experience in 182 patients. J Acquir Immune Defic Syndr 2000; 23:A11.
53. Sparano JA, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soeiro R, Henry DH, Mason B, Ratech H, Dutcher JP. Pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with HIV associated non-Hodgkin's lymphoma. Journal of Clinical Oncology 1996; 14:3026-35.
54. Sparano JA, Wiernik PH, Hu X, Sarta H, Henry DH, Ratech H. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 1998; 15:50-7.
55. Sparano JA, Lee S, Chen MG, Nazeer T, Einzig A, Ambinder RF, Henry DH, Manalo J, Li T, Von Roenn JH. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: An Eastern Cooperative Oncology Group Trial (E1494). J Clin Oncol 2004; 22:1491-500.
56. Bower M, McCall-Peat N, Ryan N, Davies L, Young AM, Gupta S, Nelson M, Gazzard B, Stebbing J. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104:2943-6.
57. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood 2002; 99:2685-93.
58. Phenix BN, Lum JJ, Nie Z, Sanchez-Dardon J, Badley AD. Antiapoptotic mechanism of HIV protease inhibitors: Preventing mitochondrial transmembrane potential loss. Blood 2001; 98:1078-85.
59. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, Franchini G, Gutierrez M, Raffeld M, Jaffe ES, Shearer G, Yarchoan R, Wilson WH. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: Impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653-9.
60. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125:1678-85.
61. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998; 10:548-51.
62. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33.
63. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92:1927-32.
64. Tirelli U, Spina M, Jaeger U, Nigra E, Blanc PL, Liberati AM, Benci A, Sparano JA. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Preliminary results of a phase I/II study. Recent Results Cancer Res 2002; 159:149-53.
65. Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, Rossi G, Nigra E, Berretta M, Cattaneo C, Rieger AC, Vaccher E, Tirelli U. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: Pooled results from 3 phase 2 trials. Blood 2005; 105:1891-7.
66. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 2002; 359:30-6.
67. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 2000; 292:310-18.
68. Hochman JH, Yamazaki M, Ohe T, Lin JH. Evaluation of drug interactions with P-glycoprotein in drug discovery: In vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Curr Drug Metab 2002; 3:257-73.
69. Chiba M, Nishime JA, Lin JH. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 1995; 275:1527-34.
70. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999; 57:1147-52.
71. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 2000; 14:1287-9.
72. Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16:531-6.
73. Simonelli C, Zanussi S, Cinelli R, Dal Maso L, Di Gennaro G, D'Andrea M, Nasti G, Spina M, Vaccher E, De Paoli P, Tirelli U. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immuno-deficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma. Clin Infect Dis 2003; 37:820-7.
74. Lascaux AS, Hemery F, Goujard C, Lesprit P, Delfraissy JF, Sobel A, Lepage E, Levy Y. Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas. AIDS Res Hum Retroviruses 2005; 21:214-20.
75. Sarker D, Thirlwell C, Nelson M, Gazzard B, Bower M. Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma. AIDS 2003; 17:861-5.
76. Kaplan LD, Kahn JO, Crowe S, Northfelt 'D, Neville P, Grossberg H, Abrams DI, Tracey J, Mills J, Volberding PA. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial. J Clin Oncol 1991; 9:929-40.
77. Sparano JA, Wiernik PH, Strack M, Leaf A, Becker N, Valentine ES. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus- and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: A highly active regimen. Blood 1993; 81:2810-15.
78. Desai J, Mitnick RJ, Henry DH, Llena J, Sparano JA. Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-hodgkin lymphoma. Cancer 1999; 86:1840-7.
79. Mazhar D, Stebbing J, Lewis R, Nelson M, Gazzard BG, Bower M. The management of meningeal lymphoma in patients with HIV in the era of HAART: Intrathecal depot cytarabine is effective and safe. Blood 2006; 107:3412-14.
80. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1-52.
81. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. JAMA 2002; 288:222-35.
82. Zanussi S, Simonelli C, D'Andrea M, Comar M, Bidoli E, Giacca M, Tirelli U, Vaccher E, De Paoli P. The effects of antineoplastic chemotherapy on HIV disease. AIDS Res Hum Retroviruses 1996; 12:1703-7.
83. Scadden DT, Zeira M, Woon A, Wang Z, Schieve L, Ikeuchi K, Lim B, Groopman JE. Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood 1992; 76:317-22.
84. Perno CF, Cooney DA, Gao, WY, Hao Z, Johns DG, Foli A, Hartman NR, Calio R, Broder S, Yarchoan R. Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood 1992; 80:995-1003.
85. Moore DA, Benepal T, Portsmouth S, Gill J, Gazzard BG. Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study. Clin Infect Dis 2001; 32:469-75.
86. Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare N, Menetrier-Caux C, Sebban C, Biron P, Blay JY. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004; 101:2675-80.
87. Miles SA, McGratten M. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol 2005; 23:247-8.
88. Diamond C, Taylor TH, Im T, Miradi M, Anton-Culver H. Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy. Hematol Oncol 2006; 10:10.
89. Cortes J, Thomas D, Rios A, Koller C, O'Brien S, Jeha S, Faderl S, Kantarjian H. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94:1492-9.
90. Rossi G, Donisi A, Casari S, Re A, Cadeo G-P, Carosi G. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 1999; 86:2391-7.
91. Bower M, Gazzard B, Mandalia S, Newsom-Davis T, Thirlwell C, Dhillon T, Young AM, Powles T, Gaya A, Nelson M, Stebbing J. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 2005; 143:265-73.